|
413 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
556 Trials |
|
44796 News |
|
| «12...616617618619620621622623624625626...627628» |
- veliparib (ABT-888) / AbbVie
New P1/2 trial, PARP Biomarker, Metastases: Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer (clinicaltrials.gov) - Oct 18, 2012
P1/2, N=110, Suspended, Sponsor: National Cancer Institute (NCI)
- Enrollment closed, FDG PET: FDG-Positron Emission Tomography (PET)/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients (clinicaltrials.gov) - Oct 18, 2012
P=N/A, N=200, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 18, 2012
P1/2, N=64, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Kevetrin (thioureidobutyronitrile) / Innovation Pharma
Enrollment open: A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 17, 2012
P1, N=40, Recruiting, Sponsor: Cellceutix Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 17, 2012
P2, N=72, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Inlyta (axitinib) / Pfizer
Trial completion, Combination therapy, Metastases: Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 17, 2012
P1, N=22, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change: POMOSCH: Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=963, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=790 --> 963
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Trial initiation date: CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") (clinicaltrials.gov) - Oct 14, 2012
P4, N=180, Recruiting, Sponsor: University of Pittsburgh
N=790 --> 963 Initiation date: Jul 2012 --> Oct 2012
- ||||||| Fiprima (filgrastim biosimilar) / Eurofarma
Trial completion, Head-to-Head: A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer (clinicaltrials.gov) - Oct 14, 2012
P3, N=220, Completed, Sponsor: Eurofarma Laboratorios S.A.
Initiation date: Jul 2012 --> Oct 2012 Recruiting --> Completed
- ||||| itraconazole / Generic mfg.
New P4 trial: A Study of Empirical Antifungal Therapy With Itraconazole (clinicaltrials.gov) - Oct 11, 2012
P4, N=138, Completed, Sponsor: Janssen Korea, Ltd., Korea
- decitabine / Generic mfg.
Enrollment closed: Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 9, 2012
P1/2, N=50, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche
New P2 trial, Metastases: TRAXHER2: A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) (clinicaltrials.gov) - Oct 4, 2012
P2, N=130, Recruiting, Sponsor: Hoffmann-La Roche
- Trial termination: The Role of ImmuKnow (clinicaltrials.gov) - Oct 3, 2012
P4, N=40, Terminated, Sponsor: CAMC Health System
Recruiting --> Active, not recruiting Recruiting --> Terminated; The PI is relocating to another State/ another hospital
- || serabelisib (MLN1117) / Takeda
Enrollment change: Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer (clinicaltrials.gov) - Oct 3, 2012
P1, N=124, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Terminated; The PI is relocating to another State/ another hospital N=60 --> 124
- ||||| Jakafi (ruxolitinib) / Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
New P1/2 trial, Combination therapy: Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients (clinicaltrials.gov) - Oct 3, 2012
P1/2, N=56, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Erbitux (cetuximab) / Eli Lilly
New P1 trial: Anti-EGFR Immunoliposomes in Solid Tumors (clinicaltrials.gov) - Oct 3, 2012
P1, N=26, Completed, Sponsor: University Hospital, Basel, Switzerland
- |||| docetaxel / Generic mfg.
Trial completion: Grano-Tax: A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen (clinicaltrials.gov) - Oct 3, 2012
P4, N=403, Completed, Sponsor: Sanofi
N=60 --> 124 Active, not recruiting --> Completed
- || Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen
Enrollment closed, Metastases: A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies (clinicaltrials.gov) - Oct 2, 2012
P1, N=90, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | pimasertib (AS703026) / Day One Biopharma
Enrollment change, Metastases: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 30, 2012
P2, N=16, Completed, Sponsor: EMD Serono
Recruiting --> Active, not recruiting N=214 --> 16
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment open: Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) - Sep 30, 2012
P1/2, N=118, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=214 --> 16 Not yet recruiting --> Recruiting
- | pimasertib (AS703026) / Day One Biopharma
Trial completion, Metastases: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 30, 2012
P2, N=16, Completed, Sponsor: EMD Serono
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes (clinicaltrials.gov) - Sep 27, 2012
P2, N=16, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Diagnostic assay: Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=200, Recruiting, Sponsor: Heidelberg University
- | Jakafi (ruxolitinib) / Incyte, Farydak (panobinostat) / Secura Bio
New P1/2 trial, Epigenetic controller: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (clinicaltrials.gov) - Sep 24, 2012
P1/2, N=58, Recruiting, Sponsor: John Mascarenhas
- || Tepmetko (tepotinib) / EMD Serono
Enrollment change: EMR200095_001: First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 23, 2012
P1, N=119, Recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed N=96 --> 119
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed: PALOMA-1;TRIO-18: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
N=96 --> 119 Recruiting --> Active, not recruiting
- lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial initiation date: ViLen 001: Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Sep 22, 2012
P2, N=6, Recruiting, Sponsor: Tel-Aviv Sourasky Medical Center
Recruiting --> Active, not recruiting Initiation date: Mar 2010 --> Aug 2011
- gemcitabine / Generic mfg.
Trial withdrawal, Metastases: Management of Metastatic Breast Cancer in Frail Patients (clinicaltrials.gov) - Sep 20, 2012
P2, N=0, Withdrawn, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Initiation date: Mar 2010 --> Aug 2011 Active, not recruiting --> Withdrawn
- ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Trial termination, Combination therapy, Monotherapy: Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=351, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Withdrawn Active, not recruiting --> Terminated; low accrual
- ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Enrollment change, Combination therapy, Monotherapy: Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=351, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=530 --> 351
- ||| albumin-bound paclitaxel / Generic mfg.
Metastases: Nabucco: Non-interventional Study With Nab-Paclitaxel (Abraxane (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=700, Recruiting, Sponsor: iOMEDICO AG
- | cisplatin / Generic mfg., pemetrexed / Generic mfg.
Trial completion: Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer (clinicaltrials.gov) - Sep 19, 2012
P1/2, N=49, Completed, Sponsor: Eli Lilly and Company
N=530 --> 351 Active, not recruiting --> Completed
- Trial initiation date, Metastases: Single Dose of Intravenous rhTNF-? and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Sep 17, 2012
P1, N=21, Suspended, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Jan 2013
- Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment change: Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform (clinicaltrials.gov) - Sep 17, 2012
P1, N=36, Active, not recruiting, Sponsor: Boehringer Ingelheim
Initiation date: Jan 2012 --> Jan 2013 N=30 --> 36
- ||| Ninlaro (ixazomib) / Takeda
Trial completion, Metastases: A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Sep 13, 2012
P1, N=116, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=30 --> 36 Active, not recruiting --> Completed
- |||| Arzerra (ofatumumab) / Novartis, Genmab
Trial completion: HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab (clinicaltrials.gov) - Sep 12, 2012
P2, N=223, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Registry of Febrile Neutropenia and Invasive Fungal Infections (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=100, Recruiting, Sponsor: Chang Gung Memorial Hospital
- ||||| Ibrance (palbociclib) / Pfizer
New P1/2 trial: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
New P1 trial, Metastases: Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer (clinicaltrials.gov) - Sep 10, 2012
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
- |||| capecitabine / Generic mfg.
Enrollment open, Metastases: X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=60, Recruiting, Sponsor: John Strickler, M.D.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Mycamine (micafungin) / Astellas
Enrollment open, Head-to-Head: Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases (clinicaltrials.gov) - Sep 10, 2012
P2, N=154, Recruiting, Sponsor: Yonsei University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- carboplatin / Generic mfg., paclitaxel / Generic mfg.
Clinical: Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer (clinicaltrials.gov) - Sep 5, 2012
P=N/A, N=750, Recruiting, Sponsor: Asan Medical Center
- Trial withdrawal: A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia (clinicaltrials.gov) - Sep 3, 2012
P1, N=0, Withdrawn, Sponsor: Enzon Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Terminated --> Withdrawn
- Enrollment change: A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia (clinicaltrials.gov) - Sep 3, 2012
P1, N=0, Withdrawn, Sponsor: Enzon Pharmaceuticals, Inc.
Terminated --> Withdrawn N=24 --> 0
- pimasertib (AS703026) / Day One Biopharma
Enrollment open, Monotherapy: EMR 200066-010: A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy (clinicaltrials.gov) - Sep 3, 2012
P1, N=48, Recruiting, Sponsor: Merck KGaA
N=24 --> 0 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment change: Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Sep 1, 2012
P1/2, N=70, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting N=134 --> 70
- ||||| dexamethasone / Generic mfg., carfilzomib / Generic mfg.
Combination therapy: CHAMPION 1: A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (clinicaltrials.gov) - Aug 30, 2012
P1/2, N=160, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- alisertib (MLN8237) / Puma
New P1 trial, Metastases: Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Aug 30, 2012
P1, N=39, Recruiting, Sponsor: Washington University School of Medicine
- |||||||||| Dulastin (tripegfilgrastim) - Dong / A
New P3 trial: Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia (clinicaltrials.gov) - Aug 27, 2012
P3, N=74, Completed, Sponsor: Dong-A Pharmaceutical Co., Ltd.
- || Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Enrollment change, Combination therapy: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Aug 23, 2012
P1, N=70, Recruiting, Sponsor: Genentech
N=134 --> 70 N=7070 --> 70